Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Opus Genetics (IRD) Revenue (2020 - 2026)

Opus Genetics has reported Revenue over the past 8 years, most recently at $2.2 million for Q1 2026.

  • Quarterly Revenue fell 50.64% to $2.2 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $12.0 million through Mar 2026, down 12.22% year-over-year, with the annual reading at $14.2 million for FY2025, 29.15% up from the prior year.
  • Revenue was $2.2 million for Q1 2026 at Opus Genetics, down from $3.9 million in the prior quarter.
  • Over five years, Revenue peaked at $39.8 million in Q4 2022 and troughed at $1.1 million in Q2 2024.
  • The 5-year median for Revenue is $3.4 million (2023), against an average of $6.2 million.
  • Year-over-year, Revenue tumbled 95.76% in 2023 and then soared 159.17% in 2025.
  • A 5-year view of Revenue shows it stood at $39.8 million in 2022, then tumbled by 95.76% to $1.7 million in 2023, then surged by 154.41% to $4.3 million in 2024, then fell by 10.16% to $3.9 million in 2025, then plummeted by 44.19% to $2.2 million in 2026.
  • Per Business Quant, the three most recent readings for IRD's Revenue are $2.2 million (Q1 2026), $3.9 million (Q4 2025), and $3.1 million (Q3 2025).